FindTrial
Sign In

Feasibility of ultra high field 7.0. Tesla MR Spectroscopy for breast cancer detection and monitoring of neo-adjuvant chemotherapy efficacy

Feasibility of ultra high field 7.0. Tesla MR Spectroscopy for breast cancer detection and monitoring of neo-adjuvant chemotherapy efficacy - 7T MRS breast cancer study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35742
Enrollment
30
Registered
2011-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast neoplasm

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Females - Group 1: patients selected for neo-adjuvant chemotherapy - Group 2: patients with BIRADS 4c or 5 classification on mammography, US or lower field MRI, selected for surgery - Group 3: healthy volunteers

Exclusion criteria

Exclusion criteria: - Any prior surgery or radiotherapy to the ipsilateral breast - Karnofsky score

Design outcomes

Primary

MeasureTime frame
1. Sensitivity of 7T MRS detection of histological proven breast cancer. The in vivo 7T MRS data will be compared to ex vivo measurements with HR-MAS and LC-MS. 2. Sensitivity of 7T MRS to monitor neo-adjuvant chemotherapy effects in membrane metabolism—

Secondary

MeasureTime frame
-—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)